Nasal spray vaccine aims to protect kids from two breathing viruses
NCT ID NCT06546423
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested two experimental nasal spray vaccines in 24 children aged 2 to 5 years. The vaccines target two viruses that can cause breathing problems: human metapneumovirus (HMPV) and parainfluenza virus type 3 (HPIV3). The main goal was to see if the vaccines are safe and trigger an immune response. Children received a single dose of one of the two vaccines or a placebo, and were monitored for 6 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN METAPNEUMOVIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CIR - Rangos, Johns Hopkins Bloomberg School of Public Health
Baltimore, Maryland, 21205, United States
-
CIR South
Columbia, Maryland, 21045, United States
-
University of Rochester Medical Center
Rochester, New York, 14642, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.